Life expectancies of Japanese patients with rheumatoid arthritis: a review of deaths over a 20-year period

Abstract We investigated trends in life expectancy in rheumatoid arthritis (RA) patients, reviewing records for 286 patients (204 female, 82 male) who had died over the past 20 years. The average age at death was 68.8 years before 1990, increasing to 72.1 years after 2001. Trends in disease modifyin...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Shinomiya, Fumio [verfasserIn] Mima, Noriaki [verfasserIn] Nanba, Keiichirou [verfasserIn] Tani, Kenji [verfasserIn] Nakano, Shunji [verfasserIn] Egawa, Hiroshi [verfasserIn] Sakai, Toshinori [verfasserIn] Miyoshi, Hideaki [verfasserIn] Hamada, Daisuke [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2008

Schlagwörter:	Activities of daily living Disease modifying anti-rheumatic drug Life expectancy Rheumatoid arthritis

Übergeordnetes Werk:	Enthalten in: Modern rheumatology - Oxford : Oxford University Press, 2000, 18(2008), 2 vom: 04. März, Seite 165-169
Übergeordnetes Werk:	volume:18 ; year:2008 ; number:2 ; day:04 ; month:03 ; pages:165-169

Links:	Volltext

DOI / URN:	10.1007/s10165-008-0031-6

Katalog-ID:	SPR009020349

Internformat


LEADER	01000caa a22002652 4500
001	SPR009020349
003	DE-627
005	20230519115543.0
007	cr uuu---uuuuu
008	201005s2008 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s10165-008-0031-6 \|2 doi
035			\|a (DE-627)SPR009020349
035			\|a (SPR)s10165-008-0031-6-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 610 \|q ASE
082	0	4	\|a 610 \|q ASE
084			\|a 44.83 \|2 bkl
100	1		\|a Shinomiya, Fumio \|e verfasserin \|4 aut
245	1	0	\|a Life expectancies of Japanese patients with rheumatoid arthritis: a review of deaths over a 20-year period
264		1	\|c 2008
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Abstract We investigated trends in life expectancy in rheumatoid arthritis (RA) patients, reviewing records for 286 patients (204 female, 82 male) who had died over the past 20 years. The average age at death was 68.8 years before 1990, increasing to 72.1 years after 2001. Trends in disease modifying anti-rheumatic drugs (DMARDs) saw gold preparations (45.2%) predominate before 1990, sulphydryl donor agents (53.6%) from 1991 to 2000, then methotrexate (43.0%) after 2001. The most common causes of death were infectious diseases up to 1995, rheumatic disease 1996–2000, and cardiovascular events and malignancies after 2001. Major advances in surgical interventions, such as joint replacement surgery, occurred after 1990. Surgical intervention followed by a period of rehabilitation maintained a favourable level of activities of daily living (ADLs), The requirements for favourable life expectancy are control of RA inflammation and maintenance of a favourable level of ADLs. Although recently developed DMARDs and biological agents show promise, caution is required to avoid serious adverse reactions. Optimum care of patients with RA will require preventive measures and early intervention for infections and rheumatic diseases, as well as for lifestyle diseases, osteoporosis and malignancies.
650		4	\|a Activities of daily living \|7 (dpeaa)DE-He213
650		4	\|a Disease modifying anti-rheumatic drug \|7 (dpeaa)DE-He213
650		4	\|a Life expectancy \|7 (dpeaa)DE-He213
650		4	\|a Rheumatoid arthritis \|7 (dpeaa)DE-He213
700	1		\|a Mima, Noriaki \|e verfasserin \|4 aut
700	1		\|a Nanba, Keiichirou \|e verfasserin \|4 aut
700	1		\|a Tani, Kenji \|e verfasserin \|4 aut
700	1		\|a Nakano, Shunji \|e verfasserin \|4 aut
700	1		\|a Egawa, Hiroshi \|e verfasserin \|4 aut
700	1		\|a Sakai, Toshinori \|e verfasserin \|4 aut
700	1		\|a Miyoshi, Hideaki \|e verfasserin \|4 aut
700	1		\|a Hamada, Daisuke \|e verfasserin \|4 aut
773	0	8	\|i Enthalten in \|t Modern rheumatology \|d Oxford : Oxford University Press, 2000 \|g 18(2008), 2 vom: 04. März, Seite 165-169 \|w (DE-627)320627497 \|w (DE-600)2023498-3 \|x 1439-7609 \|7 nnns
773	1	8	\|g volume:18 \|g year:2008 \|g number:2 \|g day:04 \|g month:03 \|g pages:165-169
856	4	0	\|u https://dx.doi.org/10.1007/s10165-008-0031-6 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_SPRINGER
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
912			\|a GBV_ILN_40
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_100
912			\|a GBV_ILN_101
912			\|a GBV_ILN_105
912			\|a GBV_ILN_151
912			\|a GBV_ILN_170
912			\|a GBV_ILN_224
912			\|a GBV_ILN_267
912			\|a GBV_ILN_285
912			\|a GBV_ILN_702
912			\|a GBV_ILN_711
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2522
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4246
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4328
912			\|a GBV_ILN_4333
936	b	k	\|a 44.83 \|q ASE
951			\|a AR
952			\|d 18 \|j 2008 \|e 2 \|b 04 \|c 03 \|h 165-169

Indexfelder

author_variant	f s fs n m nm k n kn k t kt s n sn h e he t s ts h m hm d h dh
matchkey_str	article:14397609:2008----::iexetnisfaaeeainsihhuaodrhiiaeiwf
hierarchy_sort_str	2008
bklnumber	44.83
publishDate	2008
allfields	10.1007/s10165-008-0031-6 doi (DE-627)SPR009020349 (SPR)s10165-008-0031-6-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE 44.83 bkl Shinomiya, Fumio verfasserin aut Life expectancies of Japanese patients with rheumatoid arthritis: a review of deaths over a 20-year period 2008 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract We investigated trends in life expectancy in rheumatoid arthritis (RA) patients, reviewing records for 286 patients (204 female, 82 male) who had died over the past 20 years. The average age at death was 68.8 years before 1990, increasing to 72.1 years after 2001. Trends in disease modifying anti-rheumatic drugs (DMARDs) saw gold preparations (45.2%) predominate before 1990, sulphydryl donor agents (53.6%) from 1991 to 2000, then methotrexate (43.0%) after 2001. The most common causes of death were infectious diseases up to 1995, rheumatic disease 1996–2000, and cardiovascular events and malignancies after 2001. Major advances in surgical interventions, such as joint replacement surgery, occurred after 1990. Surgical intervention followed by a period of rehabilitation maintained a favourable level of activities of daily living (ADLs), The requirements for favourable life expectancy are control of RA inflammation and maintenance of a favourable level of ADLs. Although recently developed DMARDs and biological agents show promise, caution is required to avoid serious adverse reactions. Optimum care of patients with RA will require preventive measures and early intervention for infections and rheumatic diseases, as well as for lifestyle diseases, osteoporosis and malignancies. Activities of daily living (dpeaa)DE-He213 Disease modifying anti-rheumatic drug (dpeaa)DE-He213 Life expectancy (dpeaa)DE-He213 Rheumatoid arthritis (dpeaa)DE-He213 Mima, Noriaki verfasserin aut Nanba, Keiichirou verfasserin aut Tani, Kenji verfasserin aut Nakano, Shunji verfasserin aut Egawa, Hiroshi verfasserin aut Sakai, Toshinori verfasserin aut Miyoshi, Hideaki verfasserin aut Hamada, Daisuke verfasserin aut Enthalten in Modern rheumatology Oxford : Oxford University Press, 2000 18(2008), 2 vom: 04. März, Seite 165-169 (DE-627)320627497 (DE-600)2023498-3 1439-7609 nnns volume:18 year:2008 number:2 day:04 month:03 pages:165-169 https://dx.doi.org/10.1007/s10165-008-0031-6 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_40 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_151 GBV_ILN_170 GBV_ILN_224 GBV_ILN_267 GBV_ILN_285 GBV_ILN_702 GBV_ILN_711 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2008 GBV_ILN_2026 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4328 GBV_ILN_4333 44.83 ASE AR 18 2008 2 04 03 165-169
spelling	10.1007/s10165-008-0031-6 doi (DE-627)SPR009020349 (SPR)s10165-008-0031-6-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE 44.83 bkl Shinomiya, Fumio verfasserin aut Life expectancies of Japanese patients with rheumatoid arthritis: a review of deaths over a 20-year period 2008 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract We investigated trends in life expectancy in rheumatoid arthritis (RA) patients, reviewing records for 286 patients (204 female, 82 male) who had died over the past 20 years. The average age at death was 68.8 years before 1990, increasing to 72.1 years after 2001. Trends in disease modifying anti-rheumatic drugs (DMARDs) saw gold preparations (45.2%) predominate before 1990, sulphydryl donor agents (53.6%) from 1991 to 2000, then methotrexate (43.0%) after 2001. The most common causes of death were infectious diseases up to 1995, rheumatic disease 1996–2000, and cardiovascular events and malignancies after 2001. Major advances in surgical interventions, such as joint replacement surgery, occurred after 1990. Surgical intervention followed by a period of rehabilitation maintained a favourable level of activities of daily living (ADLs), The requirements for favourable life expectancy are control of RA inflammation and maintenance of a favourable level of ADLs. Although recently developed DMARDs and biological agents show promise, caution is required to avoid serious adverse reactions. Optimum care of patients with RA will require preventive measures and early intervention for infections and rheumatic diseases, as well as for lifestyle diseases, osteoporosis and malignancies. Activities of daily living (dpeaa)DE-He213 Disease modifying anti-rheumatic drug (dpeaa)DE-He213 Life expectancy (dpeaa)DE-He213 Rheumatoid arthritis (dpeaa)DE-He213 Mima, Noriaki verfasserin aut Nanba, Keiichirou verfasserin aut Tani, Kenji verfasserin aut Nakano, Shunji verfasserin aut Egawa, Hiroshi verfasserin aut Sakai, Toshinori verfasserin aut Miyoshi, Hideaki verfasserin aut Hamada, Daisuke verfasserin aut Enthalten in Modern rheumatology Oxford : Oxford University Press, 2000 18(2008), 2 vom: 04. März, Seite 165-169 (DE-627)320627497 (DE-600)2023498-3 1439-7609 nnns volume:18 year:2008 number:2 day:04 month:03 pages:165-169 https://dx.doi.org/10.1007/s10165-008-0031-6 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_40 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_151 GBV_ILN_170 GBV_ILN_224 GBV_ILN_267 GBV_ILN_285 GBV_ILN_702 GBV_ILN_711 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2008 GBV_ILN_2026 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4328 GBV_ILN_4333 44.83 ASE AR 18 2008 2 04 03 165-169
allfields_unstemmed	10.1007/s10165-008-0031-6 doi (DE-627)SPR009020349 (SPR)s10165-008-0031-6-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE 44.83 bkl Shinomiya, Fumio verfasserin aut Life expectancies of Japanese patients with rheumatoid arthritis: a review of deaths over a 20-year period 2008 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract We investigated trends in life expectancy in rheumatoid arthritis (RA) patients, reviewing records for 286 patients (204 female, 82 male) who had died over the past 20 years. The average age at death was 68.8 years before 1990, increasing to 72.1 years after 2001. Trends in disease modifying anti-rheumatic drugs (DMARDs) saw gold preparations (45.2%) predominate before 1990, sulphydryl donor agents (53.6%) from 1991 to 2000, then methotrexate (43.0%) after 2001. The most common causes of death were infectious diseases up to 1995, rheumatic disease 1996–2000, and cardiovascular events and malignancies after 2001. Major advances in surgical interventions, such as joint replacement surgery, occurred after 1990. Surgical intervention followed by a period of rehabilitation maintained a favourable level of activities of daily living (ADLs), The requirements for favourable life expectancy are control of RA inflammation and maintenance of a favourable level of ADLs. Although recently developed DMARDs and biological agents show promise, caution is required to avoid serious adverse reactions. Optimum care of patients with RA will require preventive measures and early intervention for infections and rheumatic diseases, as well as for lifestyle diseases, osteoporosis and malignancies. Activities of daily living (dpeaa)DE-He213 Disease modifying anti-rheumatic drug (dpeaa)DE-He213 Life expectancy (dpeaa)DE-He213 Rheumatoid arthritis (dpeaa)DE-He213 Mima, Noriaki verfasserin aut Nanba, Keiichirou verfasserin aut Tani, Kenji verfasserin aut Nakano, Shunji verfasserin aut Egawa, Hiroshi verfasserin aut Sakai, Toshinori verfasserin aut Miyoshi, Hideaki verfasserin aut Hamada, Daisuke verfasserin aut Enthalten in Modern rheumatology Oxford : Oxford University Press, 2000 18(2008), 2 vom: 04. März, Seite 165-169 (DE-627)320627497 (DE-600)2023498-3 1439-7609 nnns volume:18 year:2008 number:2 day:04 month:03 pages:165-169 https://dx.doi.org/10.1007/s10165-008-0031-6 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_40 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_151 GBV_ILN_170 GBV_ILN_224 GBV_ILN_267 GBV_ILN_285 GBV_ILN_702 GBV_ILN_711 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2008 GBV_ILN_2026 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4328 GBV_ILN_4333 44.83 ASE AR 18 2008 2 04 03 165-169
allfieldsGer	10.1007/s10165-008-0031-6 doi (DE-627)SPR009020349 (SPR)s10165-008-0031-6-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE 44.83 bkl Shinomiya, Fumio verfasserin aut Life expectancies of Japanese patients with rheumatoid arthritis: a review of deaths over a 20-year period 2008 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract We investigated trends in life expectancy in rheumatoid arthritis (RA) patients, reviewing records for 286 patients (204 female, 82 male) who had died over the past 20 years. The average age at death was 68.8 years before 1990, increasing to 72.1 years after 2001. Trends in disease modifying anti-rheumatic drugs (DMARDs) saw gold preparations (45.2%) predominate before 1990, sulphydryl donor agents (53.6%) from 1991 to 2000, then methotrexate (43.0%) after 2001. The most common causes of death were infectious diseases up to 1995, rheumatic disease 1996–2000, and cardiovascular events and malignancies after 2001. Major advances in surgical interventions, such as joint replacement surgery, occurred after 1990. Surgical intervention followed by a period of rehabilitation maintained a favourable level of activities of daily living (ADLs), The requirements for favourable life expectancy are control of RA inflammation and maintenance of a favourable level of ADLs. Although recently developed DMARDs and biological agents show promise, caution is required to avoid serious adverse reactions. Optimum care of patients with RA will require preventive measures and early intervention for infections and rheumatic diseases, as well as for lifestyle diseases, osteoporosis and malignancies. Activities of daily living (dpeaa)DE-He213 Disease modifying anti-rheumatic drug (dpeaa)DE-He213 Life expectancy (dpeaa)DE-He213 Rheumatoid arthritis (dpeaa)DE-He213 Mima, Noriaki verfasserin aut Nanba, Keiichirou verfasserin aut Tani, Kenji verfasserin aut Nakano, Shunji verfasserin aut Egawa, Hiroshi verfasserin aut Sakai, Toshinori verfasserin aut Miyoshi, Hideaki verfasserin aut Hamada, Daisuke verfasserin aut Enthalten in Modern rheumatology Oxford : Oxford University Press, 2000 18(2008), 2 vom: 04. März, Seite 165-169 (DE-627)320627497 (DE-600)2023498-3 1439-7609 nnns volume:18 year:2008 number:2 day:04 month:03 pages:165-169 https://dx.doi.org/10.1007/s10165-008-0031-6 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_40 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_151 GBV_ILN_170 GBV_ILN_224 GBV_ILN_267 GBV_ILN_285 GBV_ILN_702 GBV_ILN_711 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2008 GBV_ILN_2026 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4328 GBV_ILN_4333 44.83 ASE AR 18 2008 2 04 03 165-169
allfieldsSound	10.1007/s10165-008-0031-6 doi (DE-627)SPR009020349 (SPR)s10165-008-0031-6-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE 44.83 bkl Shinomiya, Fumio verfasserin aut Life expectancies of Japanese patients with rheumatoid arthritis: a review of deaths over a 20-year period 2008 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract We investigated trends in life expectancy in rheumatoid arthritis (RA) patients, reviewing records for 286 patients (204 female, 82 male) who had died over the past 20 years. The average age at death was 68.8 years before 1990, increasing to 72.1 years after 2001. Trends in disease modifying anti-rheumatic drugs (DMARDs) saw gold preparations (45.2%) predominate before 1990, sulphydryl donor agents (53.6%) from 1991 to 2000, then methotrexate (43.0%) after 2001. The most common causes of death were infectious diseases up to 1995, rheumatic disease 1996–2000, and cardiovascular events and malignancies after 2001. Major advances in surgical interventions, such as joint replacement surgery, occurred after 1990. Surgical intervention followed by a period of rehabilitation maintained a favourable level of activities of daily living (ADLs), The requirements for favourable life expectancy are control of RA inflammation and maintenance of a favourable level of ADLs. Although recently developed DMARDs and biological agents show promise, caution is required to avoid serious adverse reactions. Optimum care of patients with RA will require preventive measures and early intervention for infections and rheumatic diseases, as well as for lifestyle diseases, osteoporosis and malignancies. Activities of daily living (dpeaa)DE-He213 Disease modifying anti-rheumatic drug (dpeaa)DE-He213 Life expectancy (dpeaa)DE-He213 Rheumatoid arthritis (dpeaa)DE-He213 Mima, Noriaki verfasserin aut Nanba, Keiichirou verfasserin aut Tani, Kenji verfasserin aut Nakano, Shunji verfasserin aut Egawa, Hiroshi verfasserin aut Sakai, Toshinori verfasserin aut Miyoshi, Hideaki verfasserin aut Hamada, Daisuke verfasserin aut Enthalten in Modern rheumatology Oxford : Oxford University Press, 2000 18(2008), 2 vom: 04. März, Seite 165-169 (DE-627)320627497 (DE-600)2023498-3 1439-7609 nnns volume:18 year:2008 number:2 day:04 month:03 pages:165-169 https://dx.doi.org/10.1007/s10165-008-0031-6 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_40 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_151 GBV_ILN_170 GBV_ILN_224 GBV_ILN_267 GBV_ILN_285 GBV_ILN_702 GBV_ILN_711 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2008 GBV_ILN_2026 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4328 GBV_ILN_4333 44.83 ASE AR 18 2008 2 04 03 165-169
language	English
source	Enthalten in Modern rheumatology 18(2008), 2 vom: 04. März, Seite 165-169 volume:18 year:2008 number:2 day:04 month:03 pages:165-169
sourceStr	Enthalten in Modern rheumatology 18(2008), 2 vom: 04. März, Seite 165-169 volume:18 year:2008 number:2 day:04 month:03 pages:165-169
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Activities of daily living Disease modifying anti-rheumatic drug Life expectancy Rheumatoid arthritis
dewey-raw	610
isfreeaccess_bool	false
container_title	Modern rheumatology
authorswithroles_txt_mv	Shinomiya, Fumio @@aut@@ Mima, Noriaki @@aut@@ Nanba, Keiichirou @@aut@@ Tani, Kenji @@aut@@ Nakano, Shunji @@aut@@ Egawa, Hiroshi @@aut@@ Sakai, Toshinori @@aut@@ Miyoshi, Hideaki @@aut@@ Hamada, Daisuke @@aut@@
publishDateDaySort_date	2008-03-04T00:00:00Z
hierarchy_top_id	320627497
dewey-sort	3610
id	SPR009020349
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR009020349</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519115543.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201005s2008 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s10165-008-0031-6</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR009020349</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s10165-008-0031-6-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.83</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Shinomiya, Fumio</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Life expectancies of Japanese patients with rheumatoid arthritis: a review of deaths over a 20-year period</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2008</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract We investigated trends in life expectancy in rheumatoid arthritis (RA) patients, reviewing records for 286 patients (204 female, 82 male) who had died over the past 20 years. The average age at death was 68.8 years before 1990, increasing to 72.1 years after 2001. Trends in disease modifying anti-rheumatic drugs (DMARDs) saw gold preparations (45.2%) predominate before 1990, sulphydryl donor agents (53.6%) from 1991 to 2000, then methotrexate (43.0%) after 2001. The most common causes of death were infectious diseases up to 1995, rheumatic disease 1996–2000, and cardiovascular events and malignancies after 2001. Major advances in surgical interventions, such as joint replacement surgery, occurred after 1990. Surgical intervention followed by a period of rehabilitation maintained a favourable level of activities of daily living (ADLs), The requirements for favourable life expectancy are control of RA inflammation and maintenance of a favourable level of ADLs. Although recently developed DMARDs and biological agents show promise, caution is required to avoid serious adverse reactions. Optimum care of patients with RA will require preventive measures and early intervention for infections and rheumatic diseases, as well as for lifestyle diseases, osteoporosis and malignancies.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Activities of daily living</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Disease modifying anti-rheumatic drug</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Life expectancy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Rheumatoid arthritis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mima, Noriaki</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nanba, Keiichirou</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tani, Kenji</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nakano, Shunji</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Egawa, Hiroshi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sakai, Toshinori</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Miyoshi, Hideaki</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hamada, Daisuke</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Modern rheumatology</subfield><subfield code="d">Oxford : Oxford University Press, 2000</subfield><subfield code="g">18(2008), 2 vom: 04. März, Seite 165-169</subfield><subfield code="w">(DE-627)320627497</subfield><subfield code="w">(DE-600)2023498-3</subfield><subfield code="x">1439-7609</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:18</subfield><subfield code="g">year:2008</subfield><subfield code="g">number:2</subfield><subfield code="g">day:04</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:165-169</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s10165-008-0031-6</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_267</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_711</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4328</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.83</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">18</subfield><subfield code="j">2008</subfield><subfield code="e">2</subfield><subfield code="b">04</subfield><subfield code="c">03</subfield><subfield code="h">165-169</subfield></datafield></record></collection>
author	Shinomiya, Fumio
spellingShingle	Shinomiya, Fumio ddc 610 bkl 44.83 misc Activities of daily living misc Disease modifying anti-rheumatic drug misc Life expectancy misc Rheumatoid arthritis Life expectancies of Japanese patients with rheumatoid arthritis: a review of deaths over a 20-year period
authorStr	Shinomiya, Fumio
ppnlink_with_tag_str_mv	@@773@@(DE-627)320627497
format	electronic Article
dewey-ones	610 - Medicine & health
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut
collection	springer
remote_str	true
illustrated	Not Illustrated
issn	1439-7609
topic_title	610 ASE 44.83 bkl Life expectancies of Japanese patients with rheumatoid arthritis: a review of deaths over a 20-year period Activities of daily living (dpeaa)DE-He213 Disease modifying anti-rheumatic drug (dpeaa)DE-He213 Life expectancy (dpeaa)DE-He213 Rheumatoid arthritis (dpeaa)DE-He213
topic	ddc 610 bkl 44.83 misc Activities of daily living misc Disease modifying anti-rheumatic drug misc Life expectancy misc Rheumatoid arthritis
topic_unstemmed	ddc 610 bkl 44.83 misc Activities of daily living misc Disease modifying anti-rheumatic drug misc Life expectancy misc Rheumatoid arthritis
topic_browse	ddc 610 bkl 44.83 misc Activities of daily living misc Disease modifying anti-rheumatic drug misc Life expectancy misc Rheumatoid arthritis
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Modern rheumatology
hierarchy_parent_id	320627497
dewey-tens	610 - Medicine & health
hierarchy_top_title	Modern rheumatology
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)320627497 (DE-600)2023498-3
title	Life expectancies of Japanese patients with rheumatoid arthritis: a review of deaths over a 20-year period
ctrlnum	(DE-627)SPR009020349 (SPR)s10165-008-0031-6-e
title_full	Life expectancies of Japanese patients with rheumatoid arthritis: a review of deaths over a 20-year period
author_sort	Shinomiya, Fumio
journal	Modern rheumatology
journalStr	Modern rheumatology
lang_code	eng
isOA_bool	false
dewey-hundreds	600 - Technology
recordtype	marc
publishDateSort	2008
contenttype_str_mv	txt
container_start_page	165
author_browse	Shinomiya, Fumio Mima, Noriaki Nanba, Keiichirou Tani, Kenji Nakano, Shunji Egawa, Hiroshi Sakai, Toshinori Miyoshi, Hideaki Hamada, Daisuke
container_volume	18
class	610 ASE 44.83 bkl
format_se	Elektronische Aufsätze
author-letter	Shinomiya, Fumio
doi_str_mv	10.1007/s10165-008-0031-6
dewey-full	610
author2-role	verfasserin
title_sort	life expectancies of japanese patients with rheumatoid arthritis: a review of deaths over a 20-year period
title_auth	Life expectancies of Japanese patients with rheumatoid arthritis: a review of deaths over a 20-year period
abstract	Abstract We investigated trends in life expectancy in rheumatoid arthritis (RA) patients, reviewing records for 286 patients (204 female, 82 male) who had died over the past 20 years. The average age at death was 68.8 years before 1990, increasing to 72.1 years after 2001. Trends in disease modifying anti-rheumatic drugs (DMARDs) saw gold preparations (45.2%) predominate before 1990, sulphydryl donor agents (53.6%) from 1991 to 2000, then methotrexate (43.0%) after 2001. The most common causes of death were infectious diseases up to 1995, rheumatic disease 1996–2000, and cardiovascular events and malignancies after 2001. Major advances in surgical interventions, such as joint replacement surgery, occurred after 1990. Surgical intervention followed by a period of rehabilitation maintained a favourable level of activities of daily living (ADLs), The requirements for favourable life expectancy are control of RA inflammation and maintenance of a favourable level of ADLs. Although recently developed DMARDs and biological agents show promise, caution is required to avoid serious adverse reactions. Optimum care of patients with RA will require preventive measures and early intervention for infections and rheumatic diseases, as well as for lifestyle diseases, osteoporosis and malignancies.
abstractGer	Abstract We investigated trends in life expectancy in rheumatoid arthritis (RA) patients, reviewing records for 286 patients (204 female, 82 male) who had died over the past 20 years. The average age at death was 68.8 years before 1990, increasing to 72.1 years after 2001. Trends in disease modifying anti-rheumatic drugs (DMARDs) saw gold preparations (45.2%) predominate before 1990, sulphydryl donor agents (53.6%) from 1991 to 2000, then methotrexate (43.0%) after 2001. The most common causes of death were infectious diseases up to 1995, rheumatic disease 1996–2000, and cardiovascular events and malignancies after 2001. Major advances in surgical interventions, such as joint replacement surgery, occurred after 1990. Surgical intervention followed by a period of rehabilitation maintained a favourable level of activities of daily living (ADLs), The requirements for favourable life expectancy are control of RA inflammation and maintenance of a favourable level of ADLs. Although recently developed DMARDs and biological agents show promise, caution is required to avoid serious adverse reactions. Optimum care of patients with RA will require preventive measures and early intervention for infections and rheumatic diseases, as well as for lifestyle diseases, osteoporosis and malignancies.
abstract_unstemmed	Abstract We investigated trends in life expectancy in rheumatoid arthritis (RA) patients, reviewing records for 286 patients (204 female, 82 male) who had died over the past 20 years. The average age at death was 68.8 years before 1990, increasing to 72.1 years after 2001. Trends in disease modifying anti-rheumatic drugs (DMARDs) saw gold preparations (45.2%) predominate before 1990, sulphydryl donor agents (53.6%) from 1991 to 2000, then methotrexate (43.0%) after 2001. The most common causes of death were infectious diseases up to 1995, rheumatic disease 1996–2000, and cardiovascular events and malignancies after 2001. Major advances in surgical interventions, such as joint replacement surgery, occurred after 1990. Surgical intervention followed by a period of rehabilitation maintained a favourable level of activities of daily living (ADLs), The requirements for favourable life expectancy are control of RA inflammation and maintenance of a favourable level of ADLs. Although recently developed DMARDs and biological agents show promise, caution is required to avoid serious adverse reactions. Optimum care of patients with RA will require preventive measures and early intervention for infections and rheumatic diseases, as well as for lifestyle diseases, osteoporosis and malignancies.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_40 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_151 GBV_ILN_170 GBV_ILN_224 GBV_ILN_267 GBV_ILN_285 GBV_ILN_702 GBV_ILN_711 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2008 GBV_ILN_2026 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4328 GBV_ILN_4333
container_issue	2
title_short	Life expectancies of Japanese patients with rheumatoid arthritis: a review of deaths over a 20-year period
url	https://dx.doi.org/10.1007/s10165-008-0031-6
remote_bool	true
author2	Mima, Noriaki Nanba, Keiichirou Tani, Kenji Nakano, Shunji Egawa, Hiroshi Sakai, Toshinori Miyoshi, Hideaki Hamada, Daisuke
author2Str	Mima, Noriaki Nanba, Keiichirou Tani, Kenji Nakano, Shunji Egawa, Hiroshi Sakai, Toshinori Miyoshi, Hideaki Hamada, Daisuke
ppnlink	320627497
mediatype_str_mv	c
isOA_txt	false
hochschulschrift_bool	false
doi_str	10.1007/s10165-008-0031-6
up_date	2024-07-04T00:20:57.922Z
_version_	1803605726123261952
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR009020349</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519115543.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201005s2008 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s10165-008-0031-6</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR009020349</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s10165-008-0031-6-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.83</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Shinomiya, Fumio</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Life expectancies of Japanese patients with rheumatoid arthritis: a review of deaths over a 20-year period</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2008</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract We investigated trends in life expectancy in rheumatoid arthritis (RA) patients, reviewing records for 286 patients (204 female, 82 male) who had died over the past 20 years. The average age at death was 68.8 years before 1990, increasing to 72.1 years after 2001. Trends in disease modifying anti-rheumatic drugs (DMARDs) saw gold preparations (45.2%) predominate before 1990, sulphydryl donor agents (53.6%) from 1991 to 2000, then methotrexate (43.0%) after 2001. The most common causes of death were infectious diseases up to 1995, rheumatic disease 1996–2000, and cardiovascular events and malignancies after 2001. Major advances in surgical interventions, such as joint replacement surgery, occurred after 1990. Surgical intervention followed by a period of rehabilitation maintained a favourable level of activities of daily living (ADLs), The requirements for favourable life expectancy are control of RA inflammation and maintenance of a favourable level of ADLs. Although recently developed DMARDs and biological agents show promise, caution is required to avoid serious adverse reactions. Optimum care of patients with RA will require preventive measures and early intervention for infections and rheumatic diseases, as well as for lifestyle diseases, osteoporosis and malignancies.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Activities of daily living</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Disease modifying anti-rheumatic drug</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Life expectancy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Rheumatoid arthritis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mima, Noriaki</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nanba, Keiichirou</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tani, Kenji</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nakano, Shunji</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Egawa, Hiroshi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sakai, Toshinori</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Miyoshi, Hideaki</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hamada, Daisuke</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Modern rheumatology</subfield><subfield code="d">Oxford : Oxford University Press, 2000</subfield><subfield code="g">18(2008), 2 vom: 04. März, Seite 165-169</subfield><subfield code="w">(DE-627)320627497</subfield><subfield code="w">(DE-600)2023498-3</subfield><subfield code="x">1439-7609</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:18</subfield><subfield code="g">year:2008</subfield><subfield code="g">number:2</subfield><subfield code="g">day:04</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:165-169</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s10165-008-0031-6</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_267</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_711</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4328</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.83</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">18</subfield><subfield code="j">2008</subfield><subfield code="e">2</subfield><subfield code="b">04</subfield><subfield code="c">03</subfield><subfield code="h">165-169</subfield></datafield></record></collection>
score	7.401087

Nicht das Richtige dabei?

Schreiben Sie uns!

Life expectancies of Japanese patients with rheumatoid arthritis: a review of deaths over a 20-year period

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?